Complex male and female coronary patients with high bleeding risk (HBR) who underwent 1 month of dual antiplatelet therapy (DAPT) after receiving percutaneous coronary intervention (PCI) with the Resolute Onyx drug-eluting stent (DES) showed no differences in 2-year outcomes, according to a subgroup analysis of the Onyx ONE Clear trial.